EMA publishes risk levels of experts based on industry connections
This article was originally published in SRA
The European Medicines Agency has published the "risk levels" of all the experts that are involved in its drug regulatory activities, based on the interests they have declared in relation to the pharmaceutical industry1. The risk levels are used together with the declarations of interests to determine the extent to which a particular expert can take part in the agency's drug authorisation and surveillance operations.
You may also be interested in...
A project is about to begin to understand the factors that influence marketing decisions in the various EU member states.
EU trade expert Hervé Jouanjean considers the reasoning behind the EU’s vaccine procurement approach and Italy's decision to block exports of AstraZeneca's COVID-19 vaccine.
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.